<?xml version="1.0" ?>
<course>
	<metadata>
		<xml_timestamp>2024-11-12T14:29:52.209032</xml_timestamp>
		<xml_version_major>0</xml_version_major>
		<xml_version_minor>3</xml_version_minor>
	</metadata>
	<demographics>
		<rt_center>Haukeland universitetssykehus</rt_center>
		<referring_hf>Voss sjukehus</referring_hf>
		<birth_year>1956</birth_year>
		<sex>mann</sex>
		<weight_at_diagnosis_kg>76.0</weight_at_diagnosis_kg>
		<height_cm>175.0</height_cm>
		<patient_id_fnr>01015625103</patient_id_fnr>
	</demographics>
	<social>
		<education_level>Videregående</education_level>
		<martial_status>Skilt</martial_status>
		<living_arrangements>Ikke i parforhold</living_arrangements>
	</social>
	<stimulantia>
		<smoking_status>Aldri røykt</smoking_status>
		<pack_years>0</pack_years>
		<month_since_stopping/>
		<non_smoking_tobacco_status>Aldri brukt</non_smoking_tobacco_status>
		<alcohol_abuse>TIdligere bruker</alcohol_abuse>
	</stimulantia>
	<function_status>
		<ecog_grade>3</ecog_grade>
		<ecog_date>2014-03-12</ecog_date>
	</function_status>
	<comorbidity>
		<item>
			<comorbidity_name>S86.9 Skade på uspesifisert muskel eller sene i legg</comorbidity_name>
			<comorbidity_code>S86.9</comorbidity_code>
			<comorbidity_term>Skade på uspesifisert muskel eller sene i legg</comorbidity_term>
			<comorbidity_terminology_version/>
			<comorbidity_category/>
			<comorbidity_date>2018-02-20</comorbidity_date>
		</item>
		<item>
			<comorbidity_name/>
			<comorbidity_code/>
			<comorbidity_term/>
			<comorbidity_terminology_version/>
			<comorbidity_category>Sykdommer i muskel-skjelettsystemet og bindevev</comorbidity_category>
			<comorbidity_date>2020-04-21</comorbidity_date>
		</item>
	</comorbidity>
	<primary_diagnosis>
		<diagnosis_name>C78.4 Metastase i tynntarm</diagnosis_name>
		<diagnosis_code>C78.4</diagnosis_code>
		<diagnosis_term>Metastase i tynntarm</diagnosis_term>
		<diagnosis_edition>ICD10</diagnosis_edition>
		<multiple_primaries>true</multiple_primaries>
		<diagnosis_localisation>Proksimalt</diagnosis_localisation>
		<diagnosis_date>2023-10-02</diagnosis_date>
		<diagnosis_method>Histologisk</diagnosis_method>
	</primary_diagnosis>
	<staging>
		<item>
			<tnm_t>T4a</tnm_t>
			<tnm_n>N0</tnm_n>
			<tnm_m>M0</tnm_m>
			<tnm_string>cT4a cN0 cM0</tnm_string>
			<tnm_edition>AJCC 8</tnm_edition>
			<tnm_stage/>
			<tnm_type>C</tnm_type>
			<other_type/>
			<other_grade/>
			<is_relapse>false</is_relapse>
			<staging_date>2024-06-10</staging_date>
		</item>
		<item>
			<tnm_t>T4a</tnm_t>
			<tnm_n>N1</tnm_n>
			<tnm_m>M0</tnm_m>
			<tnm_string>pT4a pN1 pM0</tnm_string>
			<tnm_edition>AJCC 8</tnm_edition>
			<tnm_stage/>
			<tnm_type>P</tnm_type>
			<other_type/>
			<other_grade/>
			<is_relapse>false</is_relapse>
			<staging_date>2024-07-10</staging_date>
		</item>
	</staging>
	<metastasis>
		<metastasis_diagnosed>true</metastasis_diagnosed>
		<metastasis_localisation>Upper GI</metastasis_localisation>
	</metastasis>
	<histology>
		<item>
			<histological_celltype_code>M74204</histological_celltype_code>
			<histological_celltype_description>mikroglandulær adenose</histological_celltype_description>
			<topographical_mapping_code>T51140</topographical_mapping_code>
			<topographical_mapping_description>ganeslimhinne</topographical_mapping_description>
		</item>
		<item>
			<histological_celltype_code>M76120</histological_celltype_code>
			<histological_celltype_description>Dupuytrens kontraktur</histological_celltype_description>
			<topographical_mapping_code>T54920</topographical_mapping_code>
			<topographical_mapping_description>gingiva i overkjeve</topographical_mapping_description>
		</item>
	</histology>
	<genetics>
		<item>
			<amino_acid_changes>SLC25A44</amino_acid_changes>
		</item>
		<item>
			<amino_acid_changes>ALDH4A1</amino_acid_changes>
		</item>
		<item>
			<amino_acid_changes>5,10-meTHF</amino_acid_changes>
		</item>
	</genetics>
	<previous_cancer>
		<is_previous_cancer>true</is_previous_cancer>
		<previous_cancer>
			<item>
				<previous_cancer_icd10_code>C71.7</previous_cancer_icd10_code>
				<previous_cancer_icd10_description>Ondartet svulst i hjernestamme</previous_cancer_icd10_description>
				<previous_cancer_laterality/>
				<previous_cancer_localisation/>
				<previous_cancer_diagnosis_year>1977</previous_cancer_diagnosis_year>
				<previous_cancer_rt_given>true</previous_cancer_rt_given>
			</item>
			<item>
				<previous_cancer_icd10_code>C77.50</previous_cancer_icd10_code>
				<previous_cancer_icd10_description>Mikrometastase i lymfeknute i bekken</previous_cancer_icd10_description>
				<previous_cancer_laterality/>
				<previous_cancer_localisation/>
				<previous_cancer_diagnosis_year>1989</previous_cancer_diagnosis_year>
				<previous_cancer_rt_given>false</previous_cancer_rt_given>
			</item>
		</previous_cancer>
	</previous_cancer>
	<treatment_summary>
		<item>
			<treatment_intention>Ikke kurativt (lokalkontroll)</treatment_intention>
			<treatment_type>Konkomitant</treatment_type>
			<treatment_radiotherapy>
				<course_id>123456</course_id>
				<procedure_nkpk_code>WEOA00</procedure_nkpk_code>
				<procedure_nkpk_description>Ekstern stråleterapi, høyenergetisk (MV)</procedure_nkpk_description>
			</treatment_radiotherapy>
			<treatment_systemic/>
			<treatment_surgery/>
		</item>
		<item>
			<treatment_intention>Kurativt</treatment_intention>
			<treatment_type>Konkomitant</treatment_type>
			<treatment_radiotherapy/>
			<treatment_systemic/>
			<treatment_surgery>
				<procedure_nkpk_code>CBD11</procedure_nkpk_code>
				<procedure_nkpk_description>Åpning av lapp etter rekonstruksjon av øyelokk</procedure_nkpk_description>
				<surgery_target>Primærtumor</surgery_target>
				<surgery_date>2023-07-24</surgery_date>
			</treatment_surgery>
		</item>
		<item>
			<treatment_intention>Kurativt</treatment_intention>
			<treatment_type>Adjuvant</treatment_type>
			<treatment_radiotherapy/>
			<treatment_systemic>
				<systemic_name>vorasidenib</systemic_name>
				<category>Immunterapi</category>
				<therapeutic_intent>Preoperativt</therapeutic_intent>
				<total_dosage_value>12.0</total_dosage_value>
				<total_dosage_unit>l</total_dosage_unit>
				<dosage_start_date>2023-04-10</dosage_start_date>
				<dosage_stop_date>2023-04-20</dosage_stop_date>
			</treatment_systemic>
			<treatment_surgery/>
		</item>
	</treatment_summary>
	<biological_sample>
		<item>
			<requisition_remissenr>12654f2</requisition_remissenr>
			<sample_laboratory>Haukeland universitetssykehus</sample_laboratory>
			<conclusion>Ingen bukspyttkjertel funnet</conclusion>
			<sample_date>2010-01-01</sample_date>
			<sample_type>Vev</sample_type>
			<sample_anatomical_location>Bukspyttkjertel</sample_anatomical_location>
			<sample_tumorcells_percentage/>
		</item>
		<item>
			<requisition_remissenr>5234536</requisition_remissenr>
			<sample_laboratory>Oslo universitetssykehus, Aker</sample_laboratory>
			<conclusion>Positive prøver</conclusion>
			<sample_date>2024-01-01</sample_date>
			<sample_type>Celler (cytologi)</sample_type>
			<sample_anatomical_location>Bukspyttkjertel</sample_anatomical_location>
			<sample_tumorcells_percentage>57.8</sample_tumorcells_percentage>
		</item>
	</biological_sample>
	<biomarker>
		<item>
			<biomarker_name>PSA</biomarker_name>
			<biomarker_value>127.0</biomarker_value>
			<biomarker_unit/>
			<biomarker_result/>
			<biomarker_method/>
		</item>
		<item>
			<biomarker_name>P16</biomarker_name>
			<biomarker_value/>
			<biomarker_unit/>
			<biomarker_result>Positiv</biomarker_result>
			<biomarker_method/>
		</item>
		<item>
			<biomarker_name>ENE mikroskopisk</biomarker_name>
			<biomarker_value>75.0</biomarker_value>
			<biomarker_unit>ml/mg</biomarker_unit>
			<biomarker_result>Positiv</biomarker_result>
			<biomarker_method/>
		</item>
		<item>
			<biomarker_name>Invasjonsdyp</biomarker_name>
			<biomarker_value>2.0</biomarker_value>
			<biomarker_unit>mm</biomarker_unit>
			<biomarker_result/>
			<biomarker_method>Målt invasjonsdyp</biomarker_method>
		</item>
	</biomarker>
	<ctcae>
		<item>
			<ctcae_date>2020-12-01</ctcae_date>
			<meddra_category/>
			<meddra_name>Atrial fibrillation</meddra_name>
			<ctcae_grade>3</ctcae_grade>
			<ctcae_terminology_version>5</ctcae_terminology_version>
			<meddra_terminology_version>27.1</meddra_terminology_version>
		</item>
		<item>
			<ctcae_date>2024-12-01</ctcae_date>
			<meddra_category/>
			<meddra_name>Retinal detachment</meddra_name>
			<ctcae_grade>5</ctcae_grade>
			<ctcae_terminology_version>5</ctcae_terminology_version>
			<meddra_terminology_version>27.1</meddra_terminology_version>
		</item>
		<item>
			<ctcae_date>2024-12-01</ctcae_date>
			<meddra_category>Endocrine disorders</meddra_category>
			<meddra_name/>
			<ctcae_grade>2</ctcae_grade>
			<ctcae_terminology_version>4</ctcae_terminology_version>
			<meddra_terminology_version>27.1</meddra_terminology_version>
		</item>
	</ctcae>
	<vital_status>
		<last_followup>2023-01-05</last_followup>
		<mors_date/>
	</vital_status>
	<tumor_event>
		<item>
			<progression_date>2022-04-06</progression_date>
			<progression_type>Residiv</progression_type>
			<progression_identification>Klinikk</progression_identification>
			<progression_grade>Fjernmetastase</progression_grade>
		</item>
		<item>
			<progression_date>2023-02-06</progression_date>
			<progression_type>Progresjon</progression_type>
			<progression_identification>Histologi</progression_identification>
			<progression_grade>Regional progresjon</progression_grade>
		</item>
	</tumor_event>
	<consent>
		<informed_patient_about_rt_registry>true</informed_patient_about_rt_registry>
		<informed_patient_about_broad_consent>false</informed_patient_about_broad_consent>
	</consent>
	<clinical_studies>
		<item>
			<study_name>Dahanca30 (hode-halskreft)</study_name>
			<study_contact_person>testlege 1</study_contact_person>
		</item>
		<item>
			<study_name>STDHOD9 PET/CT-veiledet strålebehandling ved hode-halskreft</study_name>
			<study_contact_person>testlege 2</study_contact_person>
		</item>
	</clinical_studies>
</course>
